Datopotamab Deruxtecan + Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non Small Cell Lung Cancer
Conditions
Metastatic Non Small Cell Lung Cancer
Trial Timeline
Jan 11, 2023 → May 11, 2029
NCT ID
NCT05555732About Datopotamab Deruxtecan + Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin
Datopotamab Deruxtecan + Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin is a phase 3 stage product being developed by Daiichi Sankyo for Metastatic Non Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05555732. Target conditions include Metastatic Non Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Non Small Cell Lung Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05555732 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Non Small Cell Lung Cancer